Retrospective Study of Genetic Testing Results Reveals Pathogenic Variants Beyond BRCA1 /2 in Hereditary Breast and Ovarian Cancer Cases in New Brunswick: Implications for Future Care
Cancer Medicine · 2025
DOI: 10.1002/cam4.70640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kelly Gauvin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Université de Sherbrooke, Sherbrooke, Québec, Canada. Hauptthemen laut MEDLINE: Genetic Testing, BRCA2 Protein, BRCA1 Protein, Hereditary Breast and Ovarian Cancer Syndrome. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation de la recherche en santé du Nouveau-Brunswick, Centre de Formation Médicale du Nouveau-Brunswick.
Abstract (Originalsprache)
Background
In Canada, founder variants in breast cancer susceptibility genes have been identified in populations residing in Québec and Newfoundland, thus demonstrating the value in characterizing the genetic profile of local populations for better clinical management. New Brunswick has a diverse, yet genetically unexplored population that includes founder Irish and Acadian ancestry, among others, and we hypothesized that this population could demonstrate potential enrichments for variants in breast cancer genes.
Methods
Health records were retrospectively analyzed for 445 cases referred to the genetics clinic in Moncton, New Brunswick, their molecular results were summarized and compared to allele frequencies from similar studies in Canada.
Results
No ethnic or age‐related correlation for specific variants could be identified. However, BRCA 1/2 variant frequency was lower than expected in the study group and variants in other susceptibility genes such as ATM and CHEK2 were higher when compared to similar studies. Perspectives This study demonstrates a distinct profile in hereditary breast cancer genetics in a previously uncharacterized population, thus adding to existing knowledge of population genetics in Atlantic Canada.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université de Sherbrooke, Sherbrooke, Québec, Canada.
- Centre de Formation Médicale du Nouveau-Brunswick, Moncton, New Brunswick, Canada.
- Vitalité Health Network, Moncton, New Brunswick, Canada.
- Department of Chemistry and Biochemistry, Université de Moncton, Moncton, New Brunswick, Canada.
- Atlantic Cancer Research Institute, Moncton, New Brunswick, Canada.
- Genolife, Saint-Louis, Québec, Canada.
ORCID-Profile: Nadia Bouhamdani, Eric Allain, Mouna Ben Amor
Förderung
- Fondation de la recherche en santé du Nouveau-Brunswick
- Centre de Formation Médicale du Nouveau-Brunswick
Zitieren
APA
Gauvin, K., Allain, V., Bouhamdani, N., Williams, C., Saheb, Y., Savoie, C., Macrae, L., Hodson, K., Zhu, Y. A., Allain, E., & Amor, M. B. (2025). Retrospective Study of Genetic Testing Results Reveals Pathogenic Variants Beyond BRCA1 /2 in Hereditary Breast and Ovarian Cancer Cases in New Brunswick: Implications for Future Care. Cancer Medicine. https://doi.org/10.1002/cam4.70640
Vancouver
Gauvin K, Allain V, Bouhamdani N, Williams C, Saheb Y, Savoie C, et al. Retrospective Study of Genetic Testing Results Reveals Pathogenic Variants Beyond BRCA1 /2 in Hereditary Breast and Ovarian Cancer Cases in New Brunswick: Implications for Future Care. Cancer Medicine. 2025. doi:10.1002/cam4.70640
BibTeX
@article{Gauvin2025,
author = {Gauvin, Kelly and Allain, Véronique and Bouhamdani, Nadia and Williams, Chloe and Saheb, Yanis and Savoie, Catherine and Macrae, Lynn and Hodson, Katherine and Zhu, Yun Amber and Allain, Eric and Amor, Mouna Ben},
title = {Retrospective Study of Genetic Testing Results Reveals Pathogenic Variants Beyond BRCA1 /2 in Hereditary Breast and Ovarian Cancer Cases in New Brunswick: Implications for Future Care},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70640}
}
EUVIMED